Novo Nordisk Insiders Stay on the Sidelines While the Company Buys Its Own Stock

Novo Nordisk's executives have not put a single krone of their own money into the company's shares since June 2024, according to reports from Danish outlets Finans and MedWatch. Only contractually awarded remuneration and anniversary shares have landed in their portfolios over that stretch — a gap that leaves the stock without one of the clearest signals of internal confidence.

Per Hansen, investment economist at Nordnet, argues the silence from the top floor carries real weight. A dearth of private purchases, in his view, undermines investor faith in a durable turnaround for the share price. Novo Nordisk declined to comment on the substance of the reports, pointing instead to the quiet period in force ahead of its next interim statement.

Buybacks Run in the Opposite Direction

On the corporate side, the purse strings are anything but tight. Under the repurchase programme launched in February, Novo Nordisk has set aside up to DKK 15bn for B-shares over twelve months starting 4 February 2026. By mid-October the group had already bought back stock worth roughly DKK 10.88bn, lifting its holding of treasury shares to 1.2% of total share capital. The most recent tranche, disclosed on Monday, covered 250,000 B-shares acquired on 12 October for DKK 64,351,856.

That steady deployment of company cash is designed to tighten the supply of shares in the market and support investors. Yet for the shareholder base, operating earnings remain the decisive variable in restoring confidence.

The full-year guidance captures the scale of the challenge. On a currency-adjusted basis, Novo Nordisk expects revenue to stagnate at best, with a decline of up to 6% in the weaker scenario. Adjusted operating profit faces an identical range — flat to 6% lower.

A Share Price Still Searching for a Floor

The market backdrop offers little comfort. At EUR 34.25 the stock was down 0.7% in Monday's session, extending its year-to-date loss to 22%. It now trades roughly 37% below its 52-week high. Analyst sentiment has added to the drag: HSBC trimmed its target for the Danish group, while BMO Capital cut its price objective from $47 to $40 about a week ago, keeping a "Market Perform" rating.

Asia Filing and a Rival's EU Nod

Beyond the capital measures, Novo Nordisk is pressing ahead with geographic expansion of its core products. Novo Nordisk Korea has filed an application with the Health Insurance Review and Assessment Service seeking reimbursement for the obesity drug Wegovy, according to media reports. A decision from the authority is still pending; a positive outcome would widen patient access in the Asian market.

Competition in oral therapies, meanwhile, is heating up. A European Medicines Agency committee recommended approval of Eli Lilly's Foundayo last Friday, per Reuters. Foundayo becomes the second oral obesity medicine to win the panel's backing, following Novo Nordisk's Wegovy tablet.

Clarity on trading and on the financial impact of the current environment should arrive on 4 November 2026, when Novo Nordisk publishes third-quarter 2026 results. Market participants will be watching global Wegovy sales most closely.